Buscar
Smith & Nephew PLC
SNNAñadir a la lista de seguimiento
31.560USD
-0.800-2.47%
Cierre 07-31 16:00（ET）Cotizaciones retrasadas 15 min
13.41BCap. mercado
28.08P/E TTM
Más Datos de Smith & Nephew PLC Compañía
Smith & Nephew plc is a portfolio medical technology company. The Company is engaged in developing, manufacturing, marketing, and selling medical devices and services. It is focused on the repair, regeneration, and replacement of soft and hard tissue. The Company's segments include Orthopaedics, Sports Medicine & ENT and Advanced Wound Management. Its Orthopaedics segment includes a range of hip, knee and shoulder implants used to replace diseased, damaged or worn joints, robotics-assisted enabling technologies that empower surgeons, and trauma products used to stabilise severe fractures and correct bone deformities. Its Sports Medicine & Ear, Nose and Throat (ENT) businesses offer advanced products and instruments used to repair or remove soft tissue. Its Advanced Wound Management portfolio provides a comprehensive set of products to meet broad and complex clinical needs, and to help healthcare professionals reduce the human and economic consequences of wounds.
Información de Smith & Nephew PLC
Símbolo de cotizaciónSNN
Nombre de la empresaSmith & Nephew PLC
Fecha de salida a bolsaSep 18, 2087
Director ejecutivoNath (Deepak S)
Número de empleados17349
Tipo de seguridadDepository Receipt
Fin del año fiscalSep 18
DirecciónBuilding 5
CiudadWATFORD
Bolsa de valoresNASDAQ OMX NASDAQ Basic NYSE
PaísUnited Kingdom
Código postalWD18 8YE
Teléfono4401923477100
Sitio Webhttps://www.smith-nephew.com/
Símbolo de cotizaciónSNN
Fecha de salida a bolsaSep 18, 2087
Director ejecutivoNath (Deepak S)
Ejecutivos de Smith & Nephew PLC
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Ajay Dhankhar, Ph.D.
Dr. Ajay Dhankhar, Ph.D.
Chief Corporate Development & Strategy Officer
Chief Corporate Development & Strategy Officer
18.46K
--
Dr. Garheng Kong, M.D., Ph.D.
Dr. Garheng Kong, M.D., Ph.D.
Independent Non-Executive Director
Independent Non-Executive Director
3.00K
--
Mr. David King
Mr. David King
Non-Executive Independent Director
Non-Executive Independent Director
2.80K
--
Mr. Deepak S. Nath
Mr. Deepak S. Nath
Chief Executive Officer, Executive Director
Chief Executive Officer, Executive Director
2.41K
+2.16%
Mr. Paul Connolly
Mr. Paul Connolly
President - Global Operations
President - Global Operations
2.40K
+2.17%
Mr. John Ma
Mr. John Ma
Non-Executive Independent Director
Non-Executive Independent Director
1.37K
+22.23%
Mr. Mizanu Kebede
Mr. Mizanu Kebede
Chief Quality and Regulatory Affairs Officer
Chief Quality and Regulatory Affairs Officer
1.29K
+1.70%
Mr. Scott Schaffner
Mr. Scott Schaffner
President - Sports Medicine
President - Sports Medicine
1.19K
+4.86%
Mr. Craig Gaffin
Mr. Craig Gaffin
President - Orthopaedics
President - Orthopaedics
894.00
+2.57%
Ms. Elga Lohler
Ms. Elga Lohler
Chief Human Resources Officer
Chief Human Resources Officer
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Ajay Dhankhar, Ph.D.
Dr. Ajay Dhankhar, Ph.D.
Chief Corporate Development & Strategy Officer
Chief Corporate Development & Strategy Officer
18.46K
--
Dr. Garheng Kong, M.D., Ph.D.
Dr. Garheng Kong, M.D., Ph.D.
Independent Non-Executive Director
Independent Non-Executive Director
3.00K
--
Mr. David King
Mr. David King
Non-Executive Independent Director
Non-Executive Independent Director
2.80K
--
Mr. Deepak S. Nath
Mr. Deepak S. Nath
Chief Executive Officer, Executive Director
Chief Executive Officer, Executive Director
2.41K
+2.16%
Mr. Paul Connolly
Mr. Paul Connolly
President - Global Operations
President - Global Operations
2.40K
+2.17%
Mr. John Ma
Mr. John Ma
Non-Executive Independent Director
Non-Executive Independent Director
1.37K
+22.23%
Preguntas frecuentes
¿Quiénes son los cinco principales accionistas de Smith & Nephew PLC?
Los cinco principales accionistas de Smith & Nephew PLC son: Dr. Ajay Dhankhar, Ph.D.
¿Cuántas instituciones poseen acciones de Smith & Nephew PLC (SNN)?
A fecha de 2026Q1, 471 instituciones poseen acciones de Smith & Nephew PLC, con un valor de mercado combinado de aproximadamente 30.95M, lo que representa el 7.25% del total de acciones. En comparación con el 2025Q4, el accionariado institucional ha aumentado en -11491314.00.
¿Cuál es la mayor fuente de ganancias de Smith & Nephew PLC?
El 2026Q1, el segmento empresarial Sports Medicine Joint Repair generó la ganancia más alta para Smith & Nephew PLC, ascendiendo a 1.07B y representando el 17.31% de la ganancia total.